Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCLK1 | O15075 | 5/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.41 |
| ▸ | MAPK7 | Q13164 | 3/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.40 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.40 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.40 |
| ▸ | DCLK2 | Q8N568 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | USP1 | O94782 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824651 | 0.82 | MGLL (0.44) | DCLK1LRRK2MAPK7TNK2PLK4 | |
| SCHEMBL3542318 | 0.81 | MAOA (0.44) | — | |
| SCHEMBL3542324 | 0.81 | MAOA (0.44) | — | |
| SCHEMBL824699 | 0.80 | PIK3CB (0.42) | DCLK1LRRK2MAPK7ABL1 | |
| SCHEMBL824661 | 0.77 | MGLL (0.41) | NTSR1 | |
| SCHEMBL824638 | 0.77 | PIK3C3 (0.41) | DCLK1LRRK2TYK2 | |
| SCHEMBL824917 | 0.77 | NPY5R (0.47) | ABL1 | |
| SCHEMBL824705 | 0.76 | TDO2 (0.45) | DCLK1LRRK2TNK2TYK2 | |
| SCHEMBL824704 | 0.76 | DCLK1 (0.37) | DCLK1LRRK2MAPK7TNK2PLK4 | |
| SCHEMBL826947 | 0.76 | DCLK1 (0.47) | DCLK1LRRK2MAPK7TNK2PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724262-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8143274-B2 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-03-27 | — | — | US | disclosed |
| US-8143274-B2 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-03-27 | — | — | US | disclosed |
| US-8143274-B2 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20070185160-A1 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185160-A1 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185160-A1 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-08-09 | — | — | US | disclosed |
| EP-1724262-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185160-A1 | 1-(2H)-isoquinolone derivative | NR3C2, NR1H4, NR3C1 | DCLK1 4530/4885LRRK2 3208/4885MAPK7 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.